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Introduction: Methicillin-resistant Staphylococcus aureus is a frequent pathogen at critical care 
services. Its presence leads to increased hospital stays and mortality risk in patients with bacteremia. 
However, the etiology of this resistance marker has not been fully studied.
Objective: To identify risk factors associated with the emergence of methicillin-resistant S. aureus 
bacteremia in critically ill patients treated at intensive care units in Bogotá, Colombia.
Materials and methods: We conducted a retrospective paired case-control study, nested in a cohort 
of patients diagnosed with S. aureus bacteremia and treated at intensive care units between 2006 and 
2008 in Bogotá. Cases were patients with positive blood culture to methicillin resistance, matched in a 
1:1 ratio with methicillin-sensitive controls isolated from the same institution and hospitalization year. 
We used conditional logistic regression to analyze the risk factors associated with the presence of 
resistance, with emphasis on prior antibiotic therapy.
Results: We included 372 patients with S. aureus bacteremia. Factors such as the use of pre-hospital 
devices: vascular (OR=1.986, 95% CI 1.038 to 3.801) and urinary (OR=2.559, 95% CI: 1.170 to 
5.596), along with the number of previously used antibiotics, were associated with the emergence 
of resistance. The number of antibiotics used previously was determined to have a gradient effect, 
particularly carbapenems.
Conclusions: The rational use of antibiotics and surveillance of exposure to surgical procedures or 
use of invasive devices are interventions that could diminish the emergence of methicillin-resistant S. 
aureus bacteremia causes.
Key words: Methicillin-resistant Staphylococcus aureus; risk factors; drug resistance, microbial; 
intensive care units; case-control studies.
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Factores de riesgo de la resistencia a meticilina de Staphylococcus aureus causante de 
bacteriemia: estudio multicéntrico de casos y controles emparejados
Introducción. Staphylococcus aureus resistente a la meticilina es uno de los agentes patógenos más 
frecuentes en las unidades de cuidados intensivos. Su presencia prolonga las hospitalizaciones y 
aumenta el riesgo de mortalidad en los pacientes con bacteriemia. Sin embargo, la etiología de este 
marcador de resistencia no ha sido completamente estudiada.
Objetivo. Determinar los factores asociados con la aparición de S. aureus resistente a la meticilina 
causante de bacteriemia en pacientes atendidos en unidades de cuidados intensivos en Bogotá.
Materiales y métodos. Se hizo un estudio retrospectivo de casos y controles emparejados, anidado 
en una cohorte de pacientes con diagnóstico de bacteriemia por S. aureus atendidos en unidades 
de cuidados intensivos de Bogotá entre 2006 y 2008. Los casos fueron pacientes con hemocultivo 
positivo para resistencia a la meticilina, emparejados 1 a 1 con controles con hemocultivos sensibles 
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a la meticilina de la misma institución y año de hospitalización. Se analizaron mediante regresión 
logística condicional los factores de riesgo asociados con la presencia de resistencia, con énfasis en 
el tratamiento previo con antibióticos.
Resultados. Se incluyeron 372 pacientes con bacteriemia por S. aureus. Factores como el uso de 
dispositivos previos a la hospitalización: vasculares (Odds ratio, OR=1,986; IC95% 1,038-3,801) y 
urinarios (OR=2,559; IC95% 1,170-5,596), así como el número de antibióticos administrado previamente, 
se asociaron con la aparición de resistencia. Se registró un efecto de gradiente con el número de 
antibióticos usados previamente, especialmente carbapenémicos.
Conclusiones. El uso racional de antibióticos y la vigilancia de la exposición a procedimientos 
quirúrgicos o al uso de dispositivos invasivos, son intervenciones que podrían disminuir la aparición de 
S. aureus resistente a meticilina causante de bacteriemia.
Palabras clave: Staphylococcus aureus resistente a meticilina; factores de riesgo; farmacorresistencia 
microbiana; unidades de cuidados intensivos; estudios de casos y controles.
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The emergence of resistant microorganisms is a 
worldwide phenomenon with serious implications 
on the quality of care and the efficiency of health 
services (1). Methicillin-resistant Staphylococcus 
aureus (MRSA) is one of the principal microorga-
nisms that cause infections in hospitals, especially 
in intensive care units (ICU). Bloodstream infections 
are notable among those caused by this agent 
(2). Methicillin resistance has been shown to 
impact clinical and economic outcomes negatively, 
particularly in terms of increased morbimortality and 
duration of hospitalization, as well as the demand 
for additional interventions to mitigate its clinical 
impact (3,4). The emergence of MRSA in the ICU 
is a priority problem because of the convergence of 
factors in critically ill patients such as the existence 
of comorbidities involving immune response effects, 
intensive use of devices and antibiotics and the 
circulation of resistant strains (5). To reduce the 
effect of the infection, studies have recommended 
anticipating the diagnosis of methicillin-resistant S. 
aureus and administering appropriate and timely 
therapy (6,7).
In order to classify patients who could become 
infected with MRSA, proven risk factors must be 
evaluated in advance to compensate for the current 
limitations in determining an early diagnosis (6). 
MRSA bacteremia emergence among ICU patients 
has been associated with several factors, which 
can be classified according to three groups: a) 
those related to the microorganisms, primarily the 
spread of resistant clones (8); b) those associated 
with the host, which include age, sex, presence 
of comorbidities (particularly chronic illnesses), 
previous use of antibiotics and invasive devices 
(9-12), and c) the characteristics of hospital and 
community environments (9,11,13), particularly 
previous use of antibiotics given the high risk 
associated with this factor and the control of cross-
transmission of microorganisms.
In Colombia, the rates of resistance to methicillin 
in S. aureus bacteremia are roughly 33% of all 
isolates. In spite of a decreasing trend in MRSA, 
both mortality as well as negative outcomes for 
the health system continue to be of concern (14). 
The early identification of patients with MRSA 
bacteremia and interventions to prevent risk 
factors related to its emergence can contribute 
to mitigating the phenomenon. Nevertheless, no 
studies exist in Colombia that adequately identify 
the factors associated with the emergence of 
methicillin resistance in patients with bloodstream 
infections treated in intensive care units. Therefore, 
the present study, conducted in a hospital network 
in the city of Bogotá, Colombia, determined the 
factors associated with the emergence of MRSA as 
a causal agent of bacteremia in critically ill patients 
treated at the ICU.
Materials and methods
Design and participants
This was a case-control study of patients diagnosed 
with S. aureus bacteremia selected from 41 intensive 
care units at 18 public and highly complex hospitals 
in Bogotá between January 2006 and December 
2008. Cases were defined as patients over 15 
years of age hospitalized in the ICU with methicillin-
resistant S. aureus bacteremia confirmed by blood 
culture according to the criteria established by 
infection surveillance systems used in Colombia 
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(15). Methicillin resistance was determined using 
the automated systems VITEK® (bioMérieux Inc., 
Marcy l’Étoile, France) and MicroScan® (Siemens 
Healthcare Diagnostics Inc; Tarrytown, New York, 
United States). We selected controls among patients 
with methicillin-susceptible S. aureus bacteremia 
(MSSA) in the institution where each case was 
diagnosed during the same year of hospitalization. 
The relationship between cases and controls 
was 1:1. We excluded patients with polymicrobial 
bacteremia and those for whom a legible clinical 
chart was unavailable, or who had previously 
been included in the study (second isolate).
Definition and recording of variables
A medical team trained in using standardized 
tools to record information collected demographic 
and clinical information from the medical record 
of each individual. Questions and discrepancies 
in the recording of the information were resolved 
in a committee composed of infection control 
professionals at each institution.
We defined use of antibiotics prior to hospitalization 
as exposure to intravenous antibiotics three months 
before the bacteremia of interest, and the use of 
invasive devices as reported clinical history of their 
use prior to hospitalization or while hospitalized 
prior to admittance to the ICU. We classified devices 
as central vascular (central venous catheter, 
transcutaneous pacemaker, prosthetic valve, 
endovascular catheter, artery vein fistula and 
acute dialysis catheter); respiratory (endotracheal 
tube, thoracostomy tube, mediastinal tube, pleural 
catheter and tracheotomy cannula); urinary (gall 
bladder catheter, cystostomy and nephrostomy 
catheter); gastrointestinal (prosthesis, biliary cathe-
ter, peritoneal catheter, nasogastric, orogastric and 
nasojejunal tubes, gastrostomy, ileostomy and 
colostomy), and other devices (central nervous 
system catheter, orthopedic devices and drainages).
We defined “history of surgery” as a report of at 
least one major surgical procedure within 30 days 
prior to the blood culture with which the bacteremia 
was diagnosed, or report of surgery within the 
previous 12 months in the case of prosthetic 
implant material, and “history of ICU stay” as a 
clinical history of at least one day of hospitalization 
in an ICU unit prior to the bacteremia and up to 6 
weeks prior to admittance to the hospital.
Comorbidities were obtained by disaggregating the 
Charlson’s index (16), which includes: Peripheral 
vascular disease, peptic ulcer, connective tissue 
disease, hepatic disease, AIDS, hemiplegia and 
dementia. The cancer category was disaggregated 
by patients with hematological tumors, solid 
tumors with metastasis and solid tumors without 
metastasis. Any patient with the following history 
was considered immunosuppressed: Use of corti-
coids over 20 mg per day for more than 15 days, 
chemotherapy during the six previous months, 
history of transplants, severe malnutrition or 
albumin <2.5 mg/dl, uncontrolled diabetes mellitus, 
organ failure (cirrhosis of the liver or renal insuf-
ficiency), neoplasm, HIV infection, autoimmune 
disease, severe burn and primary genetic immune 
deficiency disorder.
The primary infection site was defined as the likely 
location of the origin of the bacteremia according 
to the treating physician. This was classified based 
on the criteria described by Calandra, et al. (17), for 
infections in the ICU and Horan, et al. criteria (CDC) 
as: Vascular, respiratory, skin and soft tissues, and 
others, which included those less frequent (urinary, 
gastrointestinal, central nervous system, orthopedic 
and mediastinal origins) (15).
Statistical analysis
We described quantitative variables using central 
tendencies and dispersions and qualitative varia-
bles with absolute and relative frequencies 
based on the profile of susceptibility to S. aureus. 
The association between risk factors and the 
emergence of resistance was evaluated with crude 
and adjusted estimations using conditional logistic 
regression (18,19), based on the pairing conducted 
at each institution. To construct the adjusted 
model, we selected variables reported in the 
literature and progressively eliminated them using 
the backward stepwise technique. To evaluate 
the association between type of previous antibiotic 
use and methicillin resistance, we adjusted 
individual models for each group of antibiotics: 
Beta-lactams, non-carbapenems, carbapenems, 
quinolone, aminoglycosides and vancomycin. For 
each case, the final models only included variables 
with a significance level of p≤0.05. All the analyses 
were performed with the Stata version 12 statistical 
package (20). The figures were designed with 
GraphPad®, Version 6.05 (Trial) (GraphPad 
Software, Inc. La Jolla, CA, USA) (21).
Results
We included 372 subjects in the study, 186 cases 
of MRSA bacteremia, and 186 MSSA bacteremia 
paired by institution and year.
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Table 1 summarizes the distribution of the 
baseline characteristics and differences among 
groups. No statistically significant differences 
were observed among groups in terms of sex 
(p=0.250), age (p=0.918), comorbidities (p=0.340), 
immunosuppression (p=0.34), history of previous 
hospitalization (p=0.31), previous stay in the ICU 
(p=0.21), primary infection site (p=0.56) or known 
source of infection (p=0.69). Although no significant 
differences were found in history of invasive 
devices prior to hospitalization (p=0.36), some 
differences were observed among the subgroups 
corresponding to type of device.
We demonstrated significant differences between 
MRSA and MSSA with regard to history of previous 
surgery (67.2% vs. 39.2%), use of devices prior to 
hospitalization (94.6% vs. 84.9%), history of previous 
intravenous antibiotic use (76.9% vs. 30.6%) and 
place where the bacteremia was acquired.
The multivariate analysis (Table 2) demonstrated 
an association between the presence of MRSA and 
history of use of vascular catheters (OR=1.986; 
95% CI: 1.038-3.801) and of urinary catheters 
prior to hospitalization (OR=2.559; 95% CI: 1.170-
5.596).The previous use of intravenous antibiotics 
was also associated with the emergence of 
methicillin resistance. In addition, a gradient related 
to the number of antibiotic families used was found 
in the study population: One family (OR=4.565; 
95% CI: 2.541-8.203), two families (OR=12.405; 
95% CI: 5.286-29.111) and three or more families 
(OR=31.742; 95% CI: 8.967-112.367).
The effect of the type of antibiotic, adjusted by 
history of previous surgery and presence of urinary, 
respiratory and vascular catheters is summarized in 
figure 1. We found that the effect of carbapenems 
on the emergence of MRSA was greater than 
that of quinolone, beta-lactams, aminoglycosides 
and vancomycin.
Discussion
Previous intensive exposure to antibiotics emerged 
as the main risk factor for the presence of MRSA 
as a causal agent of bacteremia in the ICU of the 
hospital network in the city of Bogotá, Colombia. 
The previous use of vascular and urinary catheters 
had a similar effect. The presence of these 
histories should serve as an alert to identify at-
risk populations so as to anticipate and prevent 
the negative consequences of MRSA infection (7). 
Our study suggests that for S. aureus infections, 
the combined exposure to antibiotics and poor 
measures to control the infections increase the 
risk of resistance, as demonstrated with other 
microorganisms (22). 
In Latin America, a study by Porto, et al. demon-
strated a similar relationship between the presence 
of MRSA and the use of high dosages of cepha-
losporins, carbapenems and vancomycin as a 
monotherapy or in combination (10). As shown in 
figure 1, we independently identified the effects of 
the different types of antibiotics on the emergence of 
MRSA. The present study shows that the previous 
use of carbapenems has a significant effect on 
the emergence of methicillin resistance, followed 
by other effects also reported in the literature 
such as previous use of vancomycin, quinolone 
and beta-lactams (in order of importance) (23). 
This result can be found online in an earlier 
investigation by Tacconelli, et al., which identified 
the association of this family of antibiotics with the 
emergence of resistant microorganisms in hospitals, 
indicating patterns of consuming broad spectrum 
antimicrobials which should be reviewed locally 
(24). The indiscriminate use of antibiotics has been 
described as a factor that exerts selection pressure 
on S. aureus resistant clones in the health-care 
setting (8).
The use of invasive devices as a risk factor for 
the presence of MRSA in bloodstream infections 
has been proven by earlier studies, as reported 
by Carnicer-Pont, et al. (12). The study by Porto, 
et al. also determined that a history of vascular, 
respiratory and gastric catheters represented a risk 
factor (10). The increased risk of MRSA infection 
can be explained by factors such as bacterial 
colonization of devices, greater exposure to mani-
pulation and therefore to cross-transmission, and 
increased exposure to the use of prophylactic 
antimicrobials which could have a selective effect 
on the microorganism. An investigation performed 
at the same time as this study in one of the 
participating institutions identified a clonal spread of 
S. aureus among patients in the ICU, demonstrating 
this microorganism’s enormous potential for cross-
transmission (25).
The presence of comorbidities and the immuno-
logical status of patients have been presented 
previously as risk factors for the presence and 
prognosis of MRSA as a causal agent of bacteremia 
(9,10). Nevertheless, this was not proven in the 
study population. These variables may have been 
underreported due to the quality of the information 
given the retrospective nature of the information and 
the difficulty of verification with patient interviews.
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Table 1. Bivariate analysis using conditional logistic regression for factors associated with the emergence of methicillin-resistant S. 
aureus bacteremia 
Variables MRSA 
(N=186)
MSSA 
(N=186)
 
 
 
 
 
 
 
 
Risk factors n n p OR CI 95%
Sex (female)   70   81 0.250   1.27 0.843   1.921
Age (average SD) 58 (19.26) 58 (19.66) 0.918   0.99 0.988   1.010
Immunosuppression *   94   85 0.340   1.22 0.807   1.845
Uncontrolled diabetes   38   28 0.169   1.46 0.849   2.533
Organ failure   30   28 0.775   1.09 0.619   1.900
Cancer   18   15 0.579   1.23 0.593   2.547
Burns   11   11 1.000   1.00 0.343   2.914
Others   26   23 0.512   1.24 0.650   2.367
Comorbidities*       
Congestive heart failure   36   47 0.082   0.64 0.387   1.058
Chronic pulmonary disease   31   37 0.319   0.76 0.450   1.295
Acute myocardial infarction   25   34 0.137   0.64 0.359   1.150
Renal disease (>moderate)   31   28 0.741   1.09 0.628   1.922
Cerebrovascular disease   20   26 0.255   0.69 0.372   1.299
Diabetes mellitus type 2   40   32 0.292   1.32 0.786   2.225
Peripheral vascular disease   17   11 0.291   1.52 0.695   3.348
Cancer   20   17 0.601   1.20 0.604   2.386
Others   48   42 0.690   1.11 0.659   1.875
Previous hospitalization 105   88 0.316   1.33 0.762   2.316
Previous ICU stay   33   23 0.219   1.46 0.795   2.712
Previous surgery 125   73 0.000   3.37 2.180   5.225
Invasive devices when admitted to hospital   86   78 0.363   1.23 0.787   1.924
Type of devices*       
Central vascular accesses 166 128 0.000   4.78 2.574   8.900
Respiratory devices 136   88 0.000   3.32 2.103   5.248
Urinary catheters 145   66 0.000   3.04 1.868   4.960
Gastrointestinal devices   92   64 0.002   2.03 1.298   3.179
Others   18     6 0.016   3.18 1.239   8.198
Devices prior to bacteremia during hospitalization 176 158 0.002   3.59 1.629   7.926
Type of devices*       
Central vascular accesses   64   37 0.001   2.21 1.361   3.603
Respiratory devices   47   18 0.000   3.22 1.780   5.845
Urinary catheters   29     9 0.001   3.62 1.666   7.907
Gastrointestinal devices   34   11 0.000   3.59 1.756   7.357
Others   18     6 0.782   0.86 0.289   2.544
Antibiotic use prior to bacteremia* 143   57 0.000   7.88 4.893 12.716
Prior to hospitalization   52   22 0.000   3.92 2.005   7.668
During hospitalization 130   44 0.000   8.41 5.151 13.755
Type of antibiotic prior to bacteremia*       
Beta-lactams 129   42 0.000   8.48 5.209 13.826
Carbapenems   46     4 0.000 15.46 5.420 44.143
 Aminoglycosides   34     5 0.000   8.31 3.158 21.888
Quinolone   26     3 0.000 10.21 3.021 34.544
Vancomycin   30     9 0.000   4.23 1.890   9.474
Place where bacteremia was acquired   0.003   1.34 1.104   1.629
Community**   13   36     
Referring institution   26   26 0.015   1.26 1.229   6.840
Hospital, not ICU   42   35 0.002   3.36 1.544   7.340
Hospital, in the ICU 105   89 0.001   3.35 1.659   6.767
Source of infection is known 127 132 0.563   0.87 0.555   1.377
Primary infection site
Vascular   73   74 0.913   0.97 0.635   1.499
Respiratory   24   32 0.238   0.75 0.426   1.318
Skin and soft tissues   18   17 0.859   1.07 0.530   2.137
Others   12     9 NS
*: Not mutually exclusive variables, **: Reference category, NS: not significant
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A history of previous surgery was clearly identified 
as a factor associated with MRSA in the global as 
well as adjusted models for each type of antibiotic. 
The main explanation for this may be related to 
the risk of cross-transmission and intensive 
exposure to antibiotic use for therapeutic or pro-
phylactic purposes.
Most of the infections were considered to have 
been hospital-acquired at the treating institution 
(79.0% MRSA vs. 66.7% MSSA) or the referring 
institution (14.0% for both groups). We observed a 
predominance of infections classified as community-
acquired among patients with methicillin-sensitive 
S. aureus (13 MRSA vs. 36 MSSA). Although the 
origin of the bacteremia has been associated with 
the methicillin resistance level where community-
acquired isolations are predominantly sensitive 
to methicillin (14), the multivariate analysis did 
not find this to be a risk factor for the presence 
of MRSA, despite its bivariate association with 
hospital-acquired infection. We did not perform 
the molecular definition of the type of isolations 
and their relationships with community-acquired 
infection in the present investigation. Some reports 
in Colombia have described the presence of USA 
300 clones related with SCC mec type IV genes in 
patients with multisensitive MRSA infection (8,23), 
which changed the predominant clone towards 
the end of the 2000-2010 decade (22,26). 
The present study was retrospective and did 
not include an active search for bacteremia or 
colonization. Additional limitations were the lack 
of assessment of other variables related to the 
presence of MRSA and the use of devices such as 
prior colonization of these and other environmental 
variables. The results obtained from a hospital 
network contribute to the definition of groups at 
risk for MRSA infection. The risks were identified 
as previous exposure to invasive vascular and 
urinary catheters, a history of previous surgery 
and previous and intensive exposure to various 
antibiotics. The recognition of these risk factors 
serves as a guide for health professionals and 
services to provide differentiated and anticipatory 
care consisting of the best selection of the empirical 
antimicrobial therapy, early identification of failure 
of the established treatment and the correct 
implementation of measures to control infections in 
these patients. In order to mitigate the impact of 
infection by this microorganism on patients treated 
in intensive care units, health services need to 
locally define and implement strategies that enable 
both the early identification of MRSA infection and 
evidence-based management of this population.
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